Skip to content

Market/Novel Tech

A new gene therapy candidate – “OPGxBEST1” – has received FDA clearance from Opus Genetics for an investigational new drug application (IND) for the treatment of bestrophin-1-related IRD.   

Opus Genetics (Nasdaq: IRD) have announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for OPGx-BEST1, a… Read More »A new gene therapy candidate – “OPGxBEST1” – has received FDA clearance from Opus Genetics for an investigational new drug application (IND) for the treatment of bestrophin-1-related IRD.   

Beacon Therapeutics announce the completion of enrolment for the Phase 2/3 trial for “laru-zova”, for the treatment of XLRP.

Beacon Therapeutics Holdings Limited, based in London, UK and Cambridge, Massachusetts, have announced the completion of enrolment in its registrational Phase 2/3 VISTA trial evaluating… Read More »Beacon Therapeutics announce the completion of enrolment for the Phase 2/3 trial for “laru-zova”, for the treatment of XLRP.

Astena Therapeutics has announced an expansion of a Phase 1 / 2 study into a continuous Phase 1 / 2 / 3 trial, agreed by U.S. Food and Drug Administration (FDA).  

Atsena Therapeutics, based in Durham, North Carolina, has announced that the U.S. Food and Drug Administration (FDA) has agreed to the expansion of the company’s… Read More »Astena Therapeutics has announced an expansion of a Phase 1 / 2 study into a continuous Phase 1 / 2 / 3 trial, agreed by U.S. Food and Drug Administration (FDA).  

Potential paradigm shift of anti-VEGF treatment with sub-cutaneous injections at home, following Phase II summary results.  

Clinical trial research on the treatment of sub-cutaneous (subQ) migaldendranib (MGB), sponsored by Ashvattha Therapeutics, has announced interim results from an ongoing Phase II study… Read More »Potential paradigm shift of anti-VEGF treatment with sub-cutaneous injections at home, following Phase II summary results.  

VeonGen Therapeutics GmbH announce re-branding of the company (previously ViGeneron) and the progression of treatments for Stargardt’s disease and retinitis pigmentosa.

VeonGen Therapeutics GmbH, based in Munich, Germany, have announced the progression of two proprietary gene therapies to the clinic based on a novel gene therapy… Read More »VeonGen Therapeutics GmbH announce re-branding of the company (previously ViGeneron) and the progression of treatments for Stargardt’s disease and retinitis pigmentosa.

Ashvattha Therapeutics has announced positive Phase 2 results for subcutaneous migaldendranib, delivered via a hydroxyl dendrimer for retinal vascular disease.

Ashvattha Therapeutics, based in Redwood City, California, have announced positive interim Phase 2 results for migaldendranib (MGB) and hydroxyl dendrimer, aimed to treat retinal vascular… Read More »Ashvattha Therapeutics has announced positive Phase 2 results for subcutaneous migaldendranib, delivered via a hydroxyl dendrimer for retinal vascular disease.

Opus Genetics Inc., has announced 12-month summary results for OPGx-LCA5 – an experimental gene therapy treatment of LCA5 retinal disease. 

Opus Genetics Inc., (NASDAQ: IRD), based in Raleigh, North Carolina, has announced the one-year summary results from adult patients treated in an ongoing Phase 1/2… Read More »Opus Genetics Inc., has announced 12-month summary results for OPGx-LCA5 – an experimental gene therapy treatment of LCA5 retinal disease. 

LumiThera Inc., obtains FDA authorisation in the US on a photo-biomodulation (PBT) medical device – “Valeda” –  for the treatment of dry AMD. 

LumiThera Inc., based in Seattle, Washington, USA, has recently received the U.S. Food & Drug Administration (FDA) authorisation, marketing for “Valeda Light Delivery System” for… Read More »LumiThera Inc., obtains FDA authorisation in the US on a photo-biomodulation (PBT) medical device – “Valeda” –  for the treatment of dry AMD.